Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers

NCT04404595 is registered in ClinicalTrials.gov with CARsgen Therapeutics Co., Ltd. as lead sponsor.

NCT NCT04404595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04404595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers
Lead sponsor
CARsgen Therapeutics Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 23, 2020
Completion date
September 1, 2035
Enrollment
110 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, pancreatic cancer